Introduction
Left ventricular assist devices (LVADs) are an increasingly used treatment option for patients with advanced heart failure refractory to optimal medical therapy, either as a bridge to cardiac transplantation or destination therapy. [1] [2] [3] The introduction of the LVAD has resulted in a good long-term survival with substantial improvement in the patient's quality of life. 3 Non-invasive imaging plays an important role in the follow-up of patients with a LVAD, for the evaluation of LV function, monitoring of treatment response, and screening for potential complications. 4, 5 However, a substantial number of these patients exhibit an impaired image quality or may even deemed unsuitable for conventional imaging techniques including standard echocardiography (SE).
Multiple studies have demonstrated that contrast echocardiography (CE) may substantially improve the endocardial border delineation and the evaluation of the LV function. patients with a LVAD, particularly to overcome the limitations of SE. 8, 9 The aim of the current pilot study was to evaluate the safety, feasibility and potential of CE in patients with a novel continuousflow LVAD, type HeartMate 3. This a third generation LVAD, with a magnetically levitated impellor, which is a potential source of destruction of echocardiography contrast agents. The hypothesis of this study was that CE use was safe and feasible in patients with HeartMate 3 LVAD to improve visualization of the LV cavity and facilitates the determination of LV size.
Methods

Patient population and study protocol
This prospective study included all patients with a LVAD that underwent CE. The study protocol was approved by the Medical Ethics Committee of the Erasmus Medical Center, Rotterdam, The Netherlands. All patients provided informed consent. Consecutive ambulatory patients with a LVAD (all patients had a HeartMate 3, Abbott Laboratories, Chicago, IL, USA) because of advanced heart failure due to ischaemic or non-ischaemic cardiomyopathy were asked to participate in this prospective pilot study. All patients underwent a SE examination in conjunction with CE. Exclusion criteria were contraindications for the use of ultrasound contrast agent, such as unstable angina, acute cardiac failure, acute endocarditis, known right-to-left shunts, and known allergy for microbubble contrast agents.
Echocardiographic acquisition
The SE and CE examinations were performed using a Philips EPIQ 7C ultrasound system (Philips Medical Systems, Bothell, USA), with an X5-1 transducer. For SE and CE, a standardized image acquisition protocol based on the American Society of Echocardiography guideline was used. 10 In short, parasternal long-axis and short axis views, and apical 4-, 2-and 3-chamber views were obtained using B-mode ultrasound and colour Doppler imaging. For the CE examination, the ultrasound system was switched to its contrast mode. The contrast mode was using amplitude modulation techniques and a mechanical index of 0.1-0.5 to optimize the CE images. CE was performed using intravenous administration of SonoVue TM ultrasound contrast agent (sulphur hexafluoride microbubble suspension, Bracco S.p.A., Milan, Italy). The ultrasound contrast agent was injected in boluses of 0.5 mL, the bolus administration was repeated when necessary up to a total dose of 5.0 mL. During and after contrast administration, the patients were observed for potential side effects or complications and LVAD function parameters were monitored. For both SE and CE, cineclips were digitally stored and reviewed offline.
Echocardiographic analysis
The SE and CE studies were reviewed offline by three independent observers unaware of the clinical data. A 17-segment model of the LV was used to analyse the LV in three standard views: parasternal long-axis, apical 4-and 2-chamber view. The image quality of each LV segment on the SE and CE clips was independently scored as (i) interpretable or (ii) uninterpretable. If there was a discrepancy in the scores of the independent readers, a consensus was reached. LV end-diastolic dimension (LVEDD) and LV end-diastolic volume (LVEDV) were assessed on the SE and CE datasets using TomTec Arena software (TomTec Imaging Systems GmbH, Unterschleissheim, Germany). The LVEDD was measured from leading edge to leading edge on the parasternal long-axis view. The LVEDV was assessed with the biplane Simpson method using the 4-and 2-chamber apical view.
Statistical analyses
Statistical analyses were performed using SPSS for Windows (version 17.0, SPSS, Chicago, IL, USA) and Excel (Excel 2003, Microsoft, Redmont, USA). Continuous variables are reported as mean ± standard deviation. Categorical variables are expressed as number (%). The v 2 test was used to evaluate differences between proportions. A P-value <0.05 was considered to indicate a statistically significant difference.
Results
Patient characteristics
The patient characteristics (mean age 58±9 years, range 43-75 years, 11 (79%) men and 3 (21%) women) are summarized in Table 1 . The majority of the patients had received a LVAD because of an ischaemic cardiomyopathy (9, 64%), whereas the remaining 5 (36%) patients had a non-ischaemic cardiomyopathy. LVAD implantation was considered as a bridge to transplantation in 8 (57%) patients and a destination therapy in 6 (43%).
Safety and feasibility
All CE studies were performed without adverse reactions and were well tolerated. None of the patients had signs of an allergic reaction and no known or unknown side effects occurred during or after intravenous administration of the contrast agent. No changes in LVAD function parameters were observed during or after CE. The dose of the contrast agent that was necessary for an adequate CE examination in these patients with an LVAD was not different from the dose that is regularly used in our centre for CE in patients Image quality SE resulted in an interpretable visualization of all 17 segments in 2 (14%) patients. In the remaining 12 (86%) patients, visualization of the LV segments was impaired (range 0-16 interpretable segments). Using SE, visualization of 57% (135/238) of LV segments was possible. Per patient, SE leads to interpretable image quality in on average 9.6 ± 5.2 LV segments. CE led to an improvement in the number of interpretable LV segments in 10 (71%) patients. Figure 1 demonstrates an improved visualization of the LV endocardial borders using CE. In 4 (29%) patients, CE did not change the image interpretation. Overall, CE resulted in a significant improvement of image quality, and visualization of 79% (187/238) LV segments was possible (P < 0.001). Per patient, CE yielded visualization of on average 13.4 ± 5.8 LV segments, an improvement of 3.8 ± 2.7 segments as compared to SE.
Assessment of LVEDD was possible in all patients, both on SE (LVEDD 66 ± 14 mm) and CE (LVEDD 64 ± 11 mm). Using SE, assessment of LVEDV using the biplane Simpson method was possible in 5/14 (36%) patients on SE, with an average LVEDV of 177 ± 55 mL. In four remaining patients assessment of LVEDV on SE was possible only in the 4-chamber apical view, and in five patients assessment of LVEDV was not possible at all. Administration of contrast agent significantly improved the assessment of LVEDV (feasibility SE: 36% vs. CE: 79%, P < 0.05). Using CE, assessment of LVEDV was possible in 11/14 (79%) of patients with a LVAD (LVEDV 229 ± 68 mL). In two remaining patients assessment of LVEDV on CE was possible only in the 4-chamber apical view, and in one patient assessment of LVEDV was not possible.
Discussion
The main findings of the present study are: (i) that CE in patients with an LVAD is safe and feasible and (ii) CE significantly improves the visualization of the endocardial borders of the LV. Imaging of the LV and evaluation of LVEDV is clinically relevant to monitor changes in LV function and size in response to therapy and to detect potential complications, such as intracardiac thrombi and blood flow stasis.
Continuous-flow LVADs are increasingly being used in patients with advanced heart failure, as a bridge to LV recovery, cardiac transplantation, or as destination therapy. [1] [2] [3] The evaluation of LV shape, function and intracardiac blood flow in patients with a LVAD may be challenging. SE is currently used as the main imaging method in the evaluation of these patients. The current study demonstrates that SE in these patients is associated with a significantly impaired image quality. Several factors may explain the impaired image quality. First, the LVAD and the inflow and outflow cannulas limit the acoustic window. Second, the device may cause artefacts. Third, patients with a LVAD cannot always be optimally positioned for echocardiography. Finally, additional factors like bandages and concomitant lung disease hinder accurate visualization of segmental and global LV function. Computed tomography has been used in the evaluation of these patients, but this technique is also limited by artefacts caused by the LVAD. Additionally the use of iodinated contrast agent is a limitation of that technique, particularly in those with an impaired renal function. Cardiac magnetic resonance imaging cannot be used because of the metal components of the LVAD. The American Society of Echocardiography and the European Association of Echocardiography have recognized the clinical value of CE and issued position papers providing guidelines. [10] [11] [12] It has become clear that CE is a safe imaging modality 13, 14 that may provide improved image quality or information that cannot be obtained by SE in stable and critically ill patients. 15, 16 Clinical applications of CE include: improvement of LV endocardial border delineation, reduction of variability in assessment of LV volumes and function, increase reader confidence, and assessment of LV structural abnormalities: apical variant of hypertrophic cardiomyopathy, ventricular noncompaction, apical thrombus, aneurysm, pseudo aneurysm, myocardial rupture and intracardiac masses (tumours and thrombi). 6, 7, [10] [11] [12] Recently, CE has been proposed, in a case-report 8 and a retrospective case series, 9 as a potentially useful imaging modality in the evaluation of patients with a LVAD. Moser et al. (HeartMate II in 9, Heartmate XVE in 1 patient) underwent a CE study, of whom 2 patients had a repeat CE study. No adverse events or known side-effects occurred during or after CE. These patients underwent a CE because of a suboptimal endocardial border delineation during SE. The use of contrast agent (Definity in 9 and Optison in 3 patients) aided image interpretation in 10 (83%) CE examinations. The current prospective study confirms that CE in patients with a LVAD (all patients had a HeartMate 3) is safe, and can be performed with a regular dose of contrast agent (Sonovue). There were no signs that the LVAD caused a substantial destruction of the contrast agent. This study has clinically relevant implications. This study shows that the SE allowed visualization of 57% of LV segments. After safe and easy intravenous administration of the ultrasound contrast agent, CE resulted in visualization of 79% of LV segments. Moreover, LV size determination could be obtained more often due to improved LV visualization using CE. Clearly, segmental and global LV function and LVEDV are important parameters in patients with a LVAD to monitor alterations in response to therapy and to diagnose potential complications.
This study has several limitations. First, because this was a pilot study, the number of patients that was considered was small. Second, potential destruction of the contrast agent by the LVAD was visually assessed and could not be quantitatively assessed. Third, this study was performed with Sonovue contrast agent, and it is not clear whether the results can be extrapolated to CE using other agents. Fourth, all of the patients had a HeartMate 3 LVAD, and it is not sure whether the current results can be extrapolated to patients with other LVAD systems. Fifth, the mentioned contraindications were considered at the time of the study conception and design, recently the contraindications have been removed by the US Food and Drug Administration
Conclusion
Routine use of a contrast agent appears safe when used in patients having a new third generation LVAD and may enhance the diagnostic accuracy of transthoracic echocardiography in these patients. LV size determination can be obtained more often due to improved LV visualization using contrast agent.
